For adults with weight problems or obese with out diabetes, the novel cyclic adenosine monophosphate-biased glucagon-like peptide 1 receptor agonist often called ecnoglutide yields a superior and sustained discount in physique weight versus placebo, in keeping with a examine printed on-line June 21 in The Lancet Diabetes & Endocrinology to coincide with the annual assembly of the American Diabetes Affiliation, held from June 20 to 23 in Chicago.
Linong Ji, M.D., from the Peking College Folks’s Hospital in Beijing, and colleagues examined the efficacy and security of once-weekly ecnoglutide versus placebo for the therapy of obese or weight problems. Contributors, aged 18 to 75 with obese or weight problems, with out diabetes, have been randomly assigned to obtain subcutaneous ecnoglutide (1.2, 1.8, or 2.4 mg; 166, 166, and 167 individuals, respectively) or volume-matched placebo (165 individuals), as soon as weekly.
The researchers discovered that the least-square imply share change in physique weight at week 40 was −9.1%, −10.9%, and −13.2% within the ecnoglutide 1.2-, 1.8-, and a pair of.4-mg teams, respectively, versus 0.1% within the placebo group. The proportion of individuals who achieved at the least a 5% discount in physique weight at week 40 was 77%, 84%, and 87% within the ecnoglutide 1.2-, 1.8-, and a pair of.4-mg teams, respectively, versus 16% within the placebo group. Remedy-emergent antagonistic occasions have been noticed in 93% of every ecnoglutide dose group and in 84% of the placebo group.
“These findings suggest ecnoglutide is a potent therapeutic option for individuals with overweight or obesity, particularly considering its extended dosing range enabling personalized weight management strategies,” the authors write.
The examine was funded by Hangzhou Sciwind Biosciences, which is creating ecnoglutide.
Extra data:
Linong Ji et al, Efficacy and security of a biased GLP-1 receptor agonist ecnoglutide in adults with obese or weight problems: a multicentre, randomised, double-blind, placebo-controlled, section 3 trial, The Lancet Diabetes & Endocrinology (2025). DOI: 10.1016/S2213-8587(25)00141-X
Tricia M-M Tan, Is biased agonism useful within the therapy of weight problems with the GLP-1 receptor analogues?, The Lancet Diabetes & Endocrinology (2025). DOI: 10.1016/S2213-8587(25)00157-3
Extra Data
2025 HealthDay. All rights reserved.
Quotation:
Ecnoglutide yields superior, sustained discount in physique weight: Research (2025, June 23)
retrieved 23 June 2025
from https://medicalxpress.com/information/2025-06-ecnoglutide-yields-superior-sustained-reduction.html
This doc is topic to copyright. Other than any honest dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for data functions solely.
